Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. Pathos AI struck two licensing deals this week, expanding its oncology pipeline. Separately, Pathos entered a co-exclusive licensing agreement with AstraZeneca to advance AZD4241, a preclinical oral PROTAC designed to degrade the estrogen receptor in HER2-negative breast cancer. The resolution closes out nearly all of the company's remaining US antitrust exposure from the generic drug pricing investigations. Thanks for listening to Pharmaceutical Executive Daily.